BE899037A - Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt - Google Patents
Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt Download PDFInfo
- Publication number
- BE899037A BE899037A BE0/212476A BE212476A BE899037A BE 899037 A BE899037 A BE 899037A BE 0/212476 A BE0/212476 A BE 0/212476A BE 212476 A BE212476 A BE 212476A BE 899037 A BE899037 A BE 899037A
- Authority
- BE
- Belgium
- Prior art keywords
- agent
- composition according
- nicotine
- composition
- tablets
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 25
- 229960002715 nicotine Drugs 0.000 title claims abstract description 24
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 230000000391 smoking effect Effects 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 210000000214 mouth Anatomy 0.000 claims description 8
- 239000006172 buffering agent Substances 0.000 claims description 7
- -1 alkali metal bicarbonate Chemical class 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 230000004523 agglutinating effect Effects 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910000318 alkali metal phosphate Inorganic materials 0.000 claims description 2
- 229940096529 carboxypolymethylene Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical group 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000002585 base Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 241000208125 Nicotiana Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002610 basifying agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RFEJUZJILGIRHQ-OMDKHLBYSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-OMDKHLBYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- NHWZQIYTQZEOSJ-UHFFFAOYSA-N carbonic acid;phosphoric acid Chemical class OC(O)=O.OP(O)(O)=O NHWZQIYTQZEOSJ-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
Compsn. contains nicotine as the base or a water-soluble acid salt. It is presented in a form suitable for sucking and that each unit contains 0.1-5 mg, partic. 1 mg, of nicotine expressed as the base.
Description
Composition à sucer permettant de cesser de fumer.
La présente invention concerne des compositions de remplacement du tabac, destinées à être sucées afin d'aider un individu soit à arrêter de fumer, soit à diminuer son envie de fumer.
1) Ces compositions, destinées à être sucées, contiennent de la nicotine sous forme de base ou sous forme de sels hydrosolubles d'acide inorganique ou organique.
La contenance, par comprimé, est comprise entre 0,1 et 5 mg de nicotine exprimée en nicotine base et de préférence 1 mg.
La nicotine, en très petite dose, a une action stimulante sur le système nerveux central. Il semble que la sensation de plaisir éprouvée lorsqu'on fume, provient essentiellement de cette action stimulante et que la nicotine soit la cause principale de dépendance vis-à-vis du tabac. Le fumeur subit 2 stimuli : l'un
lié à l'habitude de porter quelque chose à la bouche et l'autre lié au besoin de nicotine.
Toute tentative visant l'arrêt de fumer doit tenir compte de ces deux facteurs.
C'est pourquoi nous avons mis au point des compositions de comprimés à sucer à base de nicotine.
En effet, sucer un comprimé occupe la bouche du fumeur et amène une libération lente et progressive de la nicotine, ce qui permet de pallier la sensation de manque éprouvée par le fumeur.
2) Les comprimés à sucer contiennent un tampon qui permet d'amener le pH de la cavité buccale à une valeur comprise entre 8 et 10 et de préférence 8,5. A ces pH, la nicotine est bien résorbée par la muqueuse buccale, condition nécessaire pour que la sensation de manque disparaisse, ce qui n'est pas le cas pour des pH acides ou neutres.
Les compositions de substitut du tabac sont de préférence rendues alcalines par adjonction d'agents basifiants acceptables du point de vue pharmacologique. Ces agents basifiants sont des substances tampons solides acceptables du point du vue physiologique pour la cavité buccale ou orale, qui exercent leur effet dans cette cavité et qui doivent donc avoir un minimum de solubilité dans l'eau. Les carbonates de phosphates de métaux alcalins constituent des agents avantageux, par exemple, le carbonate de sodium, le carbonate de potassium, les phosphates tri-et disodiques, etc, ou des mélanges de ces substances. On utilisera de préférence le phosphate disodique. Le carbonate de calcium est exclu en tant que tampon parce qu'il n'est pas suffisamment soluble dans l'eau pour se comporter comme un tampon dans la cavité buccale.
Pour augmenter encore l'effet tampon, sans élever proportionnellement le pH, on peut adjoindre un second agent tampon ou agent auxiliaire tel que les bicarbonates des métaux alcalins, par exemple le bicarbonate de sodium ou de potassium.
La quantité de ce ou de ces agents tampons contenue dans les compositions de comprimés à sucer, doit être suffisante pour élever le pH de la salive à une valeur comprise entre 8 et 10 pendant toute la durée de dissolution des comprimés.
Suivant le type de tampon utilisé, la quantité globale en tampon sera comprise, en général, entre 1
et 5 % en poids de la composition globale et de préférence 3 %.
3) La vitesse à laquelle la nicotine est libérée dépend de la vitesse de dissolution du comprimé, c'est-à-dire essentiellement de sa composition pour une personne suçant normalement.
Les compositions sont telles que les temps
de délitage des comprimés, déterminés suivant le test de désintégration décrit dans la Pharmacopée Européenne Vol. III p. 104 soient compris entre 10 minutes et
1/2 heure.
En effet, pour les temps de délitage des comprimés à sucer, la nicotine est libérée lentement et résorbée immédiatement par la muqueuse buccale, supprimant ainsi toute sensation de manque, ce qui représente une aide appréciable pour tout individu désirant arrêter de fumer.
Par contre, si les comprimés se dissolvent trop vite, la nicotine est libérée en trop grande quantité et une partie importante s'en va dans la salive et est donc avalée sans avoir eu le temps d'être résorbée au niveau de la bouche.
De ce fait, l'effet de stimulation escompté ne peut être obtenu : la sensation de manque en nicotine persiste.
La nicotine sous forme de base ou de sels doit être répartie uniformément dans l'entièreté du comprimé à sucer de telle sorte qu'elle soit libérée régulièrement pendant toute la durée de dissolution du comprimé.
La base des comprimés est constituée de sucre auquel on ajoute :
1[deg.] un agent qui empêche le sucre de s'agglomérer, favorise la granulation humide et renforce la dureté des comprimés, par exemple le carbonate de calcium
2[deg.] un ou plusieurs agents tampons permettant d'élever
le pH de la salive à une valeur comprise entre 8 et
10 pendant toute la durée de dissolution des comprimés 3[deg.] un agent agglutinant permettant d'augmenter le temps
de délitage des comprimés par exemple : la gélatine, les gommes et plus particulièrement la gomme arabique, l'empois d'amidon, le carboxypolyméthylène (carbopol), les dérivés de la cellulose tels que la méthylcellulose, l'hydroxypropyl méthylcellulose, la carboxy- <EMI ID=1.1>
4[deg.] Un agent lubrifiant par exemple : le stéarate de
magnésium, l'huile de ricin durcie, etc...
La quantité de sucre de base contenue dans les compositions de l'invention se situe entre environ
40 et 95 % en poids de la composition totale et de préférence environ 80 %.
La quantité en agent qui empêche le sucre de s'agglomérer, favorise la granulation humide et renforce la dureté des comprimés contenus dans les compositions de l'invention,se situe entre environ 1 et 30 % en poids de la composition totale et de préférence environ 6 %.
La quantité en agent agglutinant qui permet d'augmenter le temps de délitage des comprimés contenus dans les compositions de l'invention se situe entre environ 0,5 et 30 % en poids de la composition totale et de préférence environ 6 %.
La quantité en agent lubrifiant contenue dans les compositions de l'invention se situe entre environ
<EMI ID=2.1>
férence environ 2 %.
4) Exemple de fabrication d'une composition à sucer remplaçant le tabac conforme à l'invention composition 1 . pour un comprimé
<EMI ID=3.1>
fabrication : pour 100.000 comprimés
1[deg.] mélanger 94,678 kg de sucre préalablement moulu avec
5,8 kg d'hydroxypropyl méthylcellulose, 6,0 kg de carbonate de calcium léger et 3,45 kg de phosphate bisodique�
2[deg.] triturer 307 g d'hydrogénotartrate de nicotine avec
50 g de saccharine sodique et ajouter tout en triturant une partie du mélange provenant de (1[deg.]) jusqu'à obtention d'une masse assez importante;
terminer l'opération dans un mélangeur en ajoutant le restant du mélange provenant de (1[deg.]) puis laisser tourner le mélangeur pendant 30 minutes;
3[deg.] granulation humide
- préparation de la solution d'hydroxypropyl méthyllellulose.
à 200 g d'hydroxypropyl méthylcellulose, ajouter
3 litres d'eau, mélanger et chauffer jusqu'à 80[deg.] C, ajouter encore 6 litres d'eau tout en maintenant l'agitation puis laisser refroidir à température ambiante;
- au mélange provenant de (2[deg.]) on ajoute la solution d'hydroxypropyl méthylcellulose refroidie et l'on mélange l'ensemble jusqu'à obtention d'une masse bien homogène. Cette masse obtenue est tamisée, séchée puis retamisée.
4[deg.] Aux granulés obtenue,, on ajoute 2 kg de stéarate de
magnésium et l'on mélange l'ensemble pendant 30 minutes.
5[deg.] Les granulés lubrifiés sont comprimés, après avoir
choisi le type de poinçons suivant la forme désirée des comprimés afin d'obtenir une composition à sucer.
5) Autres exemples de composition conforme à l'invention.
composition 2 : pour un comprimé
<EMI ID=4.1>
composition 3 : pour un comprimé
<EMI ID=5.1>
composition 4 : pour un comprimé
<EMI ID=6.1>
composition 5 : pour un comprimé
<EMI ID=7.1>
6) Les comprimés à sucer permettent d'atteindre deux objectifs : supprimer les symptômes de manque par l'apport de nicotine et remplacer l'automatisme du geste du fumeur par le fait de sucer un comprimé.
Ils agissent donc en deux étapes : dans un premier temps, sur le comportement du fumeur et, par la suite, sur sa dépendance à l'égard de la nicotine. Une étude chimique effectuée sur 65 personnes a donné de très bons résultats et confirme l'action de ces comprimés.
Au début du traitement, les comprimés peuvent provoquer une légère irritation de la gorge. Si l'on suce trop vigoureusement un comprimé ou si on le croque, la nicotine, au lieu d'être résorbée au niveau buccal, est avalée avec la salive.
De ce fait, elle peut provoquer des nausées, aigreurs ou vomissements et pour des personnes souffrant de gastrites et d'ulcères à l'estomac, elle peut en augmenter les symptômes.
REVENDICATIONS
1. Composition permettant de cesser de fumer contenant de la nicotine sous forme de base ou
de sel hydrosoluble d'acide, caractérisée en ce qu'elle se présente sous forme d'unités à sucer et en ce qu'elle contient par unité une quantité de nicotine comprise
<EMI ID=8.1>
exprimée en base libre.
Sucking composition for quitting smoking.
The present invention relates to tobacco replacement compositions, intended to be sucked in order to help an individual either to quit smoking or to reduce his desire to smoke.
1) These compositions, intended to be sucked, contain nicotine in the form of the base or in the form of water-soluble salts of inorganic or organic acid.
The capacity, per tablet, is between 0.1 and 5 mg of nicotine expressed as nicotine base and preferably 1 mg.
Nicotine, in very small doses, has a stimulating action on the central nervous system. It seems that the feeling of pleasure experienced when smoking, comes mainly from this stimulating action and that nicotine is the main cause of dependence on tobacco. The smoker undergoes 2 stimuli: one
related to the habit of carrying something to the mouth and the other related to the need for nicotine.
Any attempt to quit smoking must take these two factors into account.
This is why we have developed nicotine-based sucking tablet compositions.
Indeed, sucking a tablet occupies the mouth of the smoker and brings about a slow and gradual release of nicotine, which makes it possible to alleviate the sensation of withdrawal experienced by the smoker.
2) The sucking tablets contain a buffer which makes it possible to bring the pH of the oral cavity to a value between 8 and 10 and preferably 8.5. At these pHs, nicotine is well absorbed by the oral mucosa, a condition necessary for the feeling of withdrawal to disappear, which is not the case for acidic or neutral pHs.
Tobacco substitute compositions are preferably made alkaline by the addition of pharmacologically acceptable basifying agents. These basifying agents are solid buffer substances which are physiologically acceptable for the oral or oral cavity, which exert their effect in this cavity and which must therefore have a minimum of solubility in water. The alkali metal phosphate carbonates are beneficial agents, for example, sodium carbonate, potassium carbonate, tri- and disodium phosphates, etc., or mixtures of these substances. Preferably disodium phosphate will be used. Calcium carbonate is excluded as a tampon because it is not sufficiently soluble in water to behave like a tampon in the oral cavity.
To further increase the buffering effect, without raising the pH proportionally, it is possible to add a second buffering agent or auxiliary agent such as bicarbonates of alkali metals, for example sodium or potassium bicarbonate.
The quantity of this or these buffering agents contained in the compositions of sucking tablets must be sufficient to raise the pH of the saliva to a value between 8 and 10 throughout the duration of dissolution of the tablets.
Depending on the type of buffer used, the overall amount of buffer will generally be between 1
and 5% by weight of the overall composition and preferably 3%.
3) The speed at which nicotine is released depends on the speed of dissolution of the tablet, i.e. essentially of its composition for a person who sucks normally.
The compositions are such that the times
of disintegration of the tablets, determined according to the disintegration test described in the European Pharmacopoeia Vol. III p. 104 are between 10 minutes and
1/2 hour.
Indeed, for the disintegration times of the sucking tablets, nicotine is slowly released and immediately absorbed by the oral mucosa, thus eliminating any feeling of withdrawal, which represents a significant help for any individual wishing to stop smoking.
On the other hand, if the tablets dissolve too quickly, nicotine is released in too large quantity and a large part goes into the saliva and is therefore swallowed without having had time to be absorbed in the mouth.
As a result, the expected stimulation effect cannot be obtained: the feeling of lack of nicotine persists.
Nicotine in base or salt form should be distributed evenly throughout the tablet to be sucked so that it is released regularly throughout the dissolution time of the tablet.
The base of the tablets consists of sugar to which we add:
1 [deg.] An agent which prevents sugar from agglomerating, promotes wet granulation and strengthens the hardness of tablets, for example calcium carbonate
2 [deg.] One or more buffer agents for raising
the pH of saliva at a value between 8 and
10 throughout the duration of dissolution of the tablets 3 [deg.] An agglutinating agent making it possible to increase the time
for disintegrating tablets, for example: gelatin, gums and more particularly gum arabic, starch paste, carboxypolymethylene (carbopol), cellulose derivatives such as methylcellulose, hydroxypropyl methylcellulose, carboxy- <EMI ID = 1.1>
4 [deg.] A lubricating agent for example: stearate
magnesium, hardened castor oil, etc.
The amount of basic sugar contained in the compositions of the invention is between approximately
40 and 95% by weight of the total composition and preferably about 80%.
The amount of agent which prevents the sugar from agglomerating, promotes wet granulation and strengthens the hardness of the tablets contained in the compositions of the invention, is between approximately 1 and 30% by weight of the total composition and preferably approximately 6%.
The amount of agglutinating agent which makes it possible to increase the disintegration time of the tablets contained in the compositions of the invention is between approximately 0.5 and 30% by weight of the total composition and preferably approximately 6%.
The amount of lubricating agent contained in the compositions of the invention is between approximately
<EMI ID = 2.1>
ference about 2%.
4) Example of the manufacture of a sucking composition replacing tobacco in accordance with the invention composition 1. for one tablet
<EMI ID = 3.1>
manufacturing: for 100,000 tablets
1 [deg.] Mix 94.678 kg of previously ground sugar with
5.8 kg of hydroxypropyl methylcellulose, 6.0 kg of light calcium carbonate and 3.45 kg of sodium phosphate �
2 [deg.] Crush 307 g of nicotine hydrogen tartrate with
50 g of sodium saccharin and add while grinding part of the mixture from (1 [deg.]) Until a fairly large mass is obtained;
finish the operation in a mixer by adding the rest of the mixture from (1 [deg.]) then let the mixer run for 30 minutes;
3 [deg.] Wet granulation
- preparation of the hydroxypropyl methyllellulose solution.
to 200 g of hydroxypropyl methylcellulose, add
3 liters of water, mix and heat up to 80 [deg.] C, add another 6 liters of water while maintaining agitation then allow to cool to room temperature;
- To the mixture coming from (2 [deg.]) the solution of cooled hydroxypropyl methylcellulose is added and the whole is mixed until a very homogeneous mass is obtained. This mass obtained is sieved, dried and then sifted.
4 [deg.] To the granules obtained, 2 kg of stearate of
magnesium and the whole is mixed for 30 minutes.
5 [deg.] The lubricated granules are compressed, after having
chose the type of punches according to the desired shape of the tablets in order to obtain a composition for sucking.
5) Other examples of composition in accordance with the invention.
composition 2: for one tablet
<EMI ID = 4.1>
composition 3: for one tablet
<EMI ID = 5.1>
composition 4: for one tablet
<EMI ID = 6.1>
composition 5: for one tablet
<EMI ID = 7.1>
6) The tablets to be sucked allow to achieve two objectives: to suppress the symptoms of withdrawal by the contribution of nicotine and to replace the automatic gesture of the smoker by the fact of sucking a tablet.
They therefore act in two stages: first, on the behavior of the smoker and, subsequently, on his dependence on nicotine. A chemical study carried out on 65 people has given very good results and confirms the action of these tablets.
At the start of treatment, the tablets may cause mild throat irritation. If a tablet is sucked too vigorously or chewed, nicotine, instead of being absorbed in the mouth, is swallowed with saliva.
As a result, it can cause nausea, bitterness, or vomiting, and for people with gastritis and stomach ulcers, it can increase symptoms.
CLAIMS
1. Composition for quitting smoking containing nicotine in the base form or
of water-soluble acid salt, characterized in that it is in the form of sucking units and in that it contains per unit an amount of nicotine included
<EMI ID = 8.1>
expressed in free base.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE0/212476A BE899037A (en) | 1984-02-29 | 1984-02-29 | Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE0/212476A BE899037A (en) | 1984-02-29 | 1984-02-29 | Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt |
| BE899037 | 1984-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE899037A true BE899037A (en) | 1984-06-18 |
Family
ID=25653966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/212476A BE899037A (en) | 1984-02-29 | 1984-02-29 | Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE899037A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003803A1 (en) * | 1986-11-18 | 1988-06-02 | Forschungsgesellschaft Rauchen Und Gesundheit Mbh | Oral administration capsule with a nicotine-containing fluid medium |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| EP0707478A1 (en) | 1993-07-26 | 1996-04-24 | Pharmacia & Upjohn Aktiebolag | Improved nicotine lozenge and therapeutic method for smoking cessation |
| US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
| EP1136487A1 (en) * | 2000-03-20 | 2001-09-26 | Nutrinova Nutrition Specialties & Food Ingredients GmbH | Nicotine salts with improved taste, process for their preparation and use thereof as smoking cessation agents |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10258738B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
-
1984
- 1984-02-29 BE BE0/212476A patent/BE899037A/en not_active IP Right Cessation
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003803A1 (en) * | 1986-11-18 | 1988-06-02 | Forschungsgesellschaft Rauchen Und Gesundheit Mbh | Oral administration capsule with a nicotine-containing fluid medium |
| EP0707478A1 (en) | 1993-07-26 | 1996-04-24 | Pharmacia & Upjohn Aktiebolag | Improved nicotine lozenge and therapeutic method for smoking cessation |
| US5549906A (en) * | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5662920A (en) * | 1993-07-26 | 1997-09-02 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US6280761B1 (en) | 1993-07-26 | 2001-08-28 | Pharmacia Ab | Nicotine lozenge |
| EP1666030A1 (en) * | 1993-07-26 | 2006-06-07 | Pfizer Health AB | Improved nicotine lozenge and therapeutic method for smoking cessation |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
| US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
| EP1136487A1 (en) * | 2000-03-20 | 2001-09-26 | Nutrinova Nutrition Specialties & Food Ingredients GmbH | Nicotine salts with improved taste, process for their preparation and use thereof as smoking cessation agents |
| US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
| US10258738B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US11471424B2 (en) | 2004-09-13 | 2022-10-18 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| US10258778B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US12011560B2 (en) | 2015-01-28 | 2024-06-18 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US11400266B2 (en) | 2015-01-28 | 2022-08-02 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US10232156B2 (en) | 2015-01-28 | 2019-03-19 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US12042614B2 (en) | 2017-01-06 | 2024-07-23 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US12515030B2 (en) | 2017-01-06 | 2026-01-06 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12017029B2 (en) | 2018-05-29 | 2024-06-25 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE899037A (en) | Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt | |
| AU764346B2 (en) | Pharmaceutical composition for the treatment of acute disorders | |
| EP1115384B1 (en) | Fentanyl composition for the treatment of acute pain | |
| CN102770138B (en) | Soft-gel lozenges containing nicotine | |
| JP3372053B2 (en) | Chewable or sucking tablets | |
| CN1553771A (en) | Nicotine-containing oral dosage forms | |
| CN111447921A (en) | Nicotine tablet | |
| NO115837B (en) | ||
| JP2015232012A (en) | Nicotine lozenge composition | |
| CA3113041C (en) | A pouch product suitable for application in an oral cavity. | |
| EP1553925A1 (en) | Modified release oral dosage form | |
| FR2611501A1 (en) | NOVEL PHARMACEUTICAL COMPOSITIONS FOR LYSINE ACETYLSALIELYLATE BUCCAL TRACT AND METHOD OF OBTAINING THE SAME | |
| WO2004032942A1 (en) | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin | |
| BE897221A (en) | LONG-TERM PRODUCTS CONTAINING SULOCTIDIL | |
| JP2003261439A (en) | Orally disintegrating preparation | |
| DK2515918T3 (en) | SMOKING SUGAR TABLET CONTAINING TOBACCO ALKALOID AND SILVER SALT | |
| KR20010000255A (en) | Irritatating-reduced oral delivery formulations of basic drugs | |
| EP1646373B1 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| FR2580497A1 (en) | PHARMACEUTICAL COMPOSITIONS IN COMPRESSES | |
| JP2002536401A (en) | Metamizole-containing foamable pharmaceutical composition | |
| EP1467737B1 (en) | Orally dispersible pharmaceutical piribedil composition | |
| RU2825844C1 (en) | Pressed nicotine lozenge | |
| JP3068084B1 (en) | Tobacco substitute composition | |
| JP2001064159A (en) | Composite granular preparation | |
| JP2025513762A (en) | Powder and its uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: TRENKER ADY Effective date: 19950228 |